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Abstract
Background: 5-hydroxytryptamine (5-HT)2B and 5-HT1B receptors are upregulated in arteries
from hypertensive DOCA-salt rats and directly by mineralocorticoids. We hypothesized that
increased 5-HT2B and 5-HT1B receptor density and contractile function would precede increased
blood pressure in DOCA-high salt rats. We performed DOCA-salt time course (days 1, 3, 5 and
7) studies using treatment groups of: DOCA-high salt, DOCA-low salt, Sham and Sham-high salt
rats.
Results: In isolated-tissue baths, DOCA-high salt aorta contracted to the 5-HT2B receptor agonist
BW723C86 on day 1; Sham aorta did not contract. The 5-HT1B receptor agonist CP93129 had no
effect in arteries from any group. On days 3, 5 and 7 CP93129 and BW723C86 contracted DOCA-
high salt and Sham-high salt aorta; Sham and DOCA-low salt aorta did not respond. Western
analysis of DOCA-high salt aortic homogenates revealed increased 5-HT2B receptor levels by day
3; 5-HT1B receptor density was unchanged. Aortic homogenates from the other groups showed
unchanged 5-HT2B and 5-HT1B receptor levels.
Conclusion: These data suggest that functional changes of 5-HT2B but not 5-HT1B receptors may
play a role in the development of DOCA-salt hypertension.
Background
5-HT is an autocoid with a myriad of actions in the cardi-
ovascular system. One of the important vascular effects of
5-HT is its ability to act as a vasoconstrictor. The 5-HT2A,
5-HT2B  and 5-HT1B  receptors have been implicated as
mediators of 5-HT-induced contraction in vascular
smooth muscle. 5-HT2A receptors mediate contraction in
many arteries including the rat thoracic aorta [1] and pul-
monary arteries [2]. 5-HT2B  receptors mediate 5-HT-
induced contraction in the rat stomach fundus, the aorta
and mesenteric arteries from hypertensive deoxycorticos-
terone acetate (DOCA)-salt rats [3–5]. The 5-HT2B recep-
tor does not appear to mediate contraction in arteries
taken from normotensive Sham rats [4,5]. Involvement of
5-HT1B receptors in mediating 5-HT-induced arterial con-
traction in normal vessels has been described in the rat tail
artery [6], human temporal artery [7], human umbilical
artery [8], human pulmonary artery [9] and human coro-
nary artery [10]. Additionally, 5-HT1B receptors mediate 5-
HT-induced contraction in mesenteric arteries from
hypertensive DOCA-salt rats [11] and pulmonary arteries
from rats with pulmonary hypertension [12,2]. Further-
more, arteries from DOCA-salt hypertensive rats have
approximately a 2-fold increase in the expression of the 5-
HT2B and 5-HT1B receptor proteins [13]. These findings
suggest that the change in the function of the 5-HT2B and
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5-HT1B receptors may be due to the alterations in the level
of the receptor proteins.
Recent in vivo studies with the selective 5-HT2B receptor
antagonist LY272015 have revealed that LY272015 low-
ered the blood pressure of DOCA-salt rats with estab-
lished hypertension [4]. These findings suggest that the 5-
HT2B receptor is endogenously activated under conditions
of hypertension to participate in the maintenance of the
elevated blood pressure. No studies have examined
whether 5-HT1B receptors are endogenously activated in
established DOCA-salt hypertension. However, activation
of 5-HT1B receptors have been implicated as a causative
factor of pulmonary hypertension. [12,14,2]. Collectively,
these studies suggest that 5-HT2B and 5-HT1B receptors can
be endogenously activated and, by their ability to mediate
5-HT-induced vasoconstriction, may participate in the
maintenance of the increased blood pressure.
We have recently found that aldosterone, in vitro, upregu-
lates the 5-HT2B and 5-HT1B receptor proteins in endothe-
lium-denuded aorta from rats with normal blood pressure
[13]. This upregulation was inhibited in the presence of
the mineralocorticoid receptor antagonist spironolactone.
Furthermore, studies in the Wistar-Furth rat model, a rat
model which is relatively resistant to the hypertensive
effects of DOCA and salt treatment [15], demonstrated
that in blood pressure matched rats, the presence of ele-
vated levels of DOCA and salt resulted in enhanced con-
traction to the 5-HT2B receptor agonist BW723C86 [16].
These findings suggest that mineralocorticoids, such as
DOCA, may be important independent regulators of these
5-HT receptors. A separation of the effects of DOCA, an
increase in blood pressure, increased levels of salt and the
combined effects of an increase in salt and DOCA on 5-HT
receptor function and protein levels has never been per-
formed. Separating the effects of these factors is necessary
to understand their contribution to regulation of 5-HT2B
and 5-HT1B receptors. Therefore, we proposed to deter-
mine when in the course of the DOCA-salt hypertension
an increase in receptor density occurs and if the increase
in the level of receptor proteins and functional response
preceded the increase in blood pressure. We hypothesized
that the increase in the 5-HT2B and 5-HT1B receptor density
and functional responses would precede the increase in
blood pressure observed in the DOCA-salt rats. We used
the rodent selective 5-HT1B receptor agonist CP93129 and
the 5-HT2B  receptor agonist BW723C86 to test this
hypothesis.
Results
On days 1, 3, 5 and 7 after surgery the rats were weighed
and the systolic blood pressure was measured. Only the
Sham rats on day seven of the protocol showed a signifi-
cant gain in body weight (data not shown). None of the
rats in the Sham-high salt, DOCA-high salt and DOCA-
low salt groups gained significant body weight during the
protocol. DOCA-high salt rats consumed significantly
more fluid than the Sham, Sham-high salt and DOCA-low
salt rats by day three and this continued through day
seven (figure 1). Additionally, rats placed on high salt
water alone increased intake significantly by day five and
remained elevated through day seven (figure 1, bottom
left and right, respectively). The Sham and DOCA-low salt
rats did not vary significantly in their fluid consumption
during the study.
DOCA-high salt rats showed a significant increase in
blood pressure by day three [average systolic blood pres-
sure (SBP) 124 ± 7.6 mm Hg, 110 ± 2.6 mm Hg and 112
± 2.4 mm Hg, DOCA-high salt and Sham, respectively]
(figure 2). The DOCA-salt rats reached hypertensive levels
by day five (average SBP 147 ± 14.0). Sham-high salt rats
had elevated blood pressures by day seven (average SBP
130 ± 9.3 mm Hg). Furthermore, by day seven the DOCA-
low salt rats had significantly lower blood pressure than
their Sham, DOCA-high salt and Sham-high salt counter-
parts (average SBP 114 ± 2.3 mm Hg, 142 ± 8.4 mm Hg,
130 ± 9.3 mm Hg and 101 ± 2.1 mm Hg, Sham, DOCA-
high salt, Sham-high salt and DOCA-low salt, respec-
tively). For further data please see Figure 9.
Contractile Studies on Day 1
Although there was no increase in systolic blood pressure
on day one, arteries from DOCA-high salt rats contracted
to the 5-HT2B receptor agonist BW723C86 (maximal con-
traction 52.5 ± 10.5 % of PE contraction). Arteries from
DOCA-low salt, Sham-high salt and Sham rats did not
respond to either BW723C86 or to the 5-HT1B receptor
agonist CP93129 (figures 3A and 3B). There was no
enhanced contraction to 5-HT observed in any of the
arteries from the treatment groups (figure 3C). These data
suggest that while 5-HT2B receptors are functional on day
one, as indicated by contraction to BW723C86, this is not
sufficient to result in an enhanced contraction to 5-HT.
Additionally, the 5-HT1B receptor agonist CP93129 was
unable to stimulate contraction, suggesting that the 5-
HT1B receptor was not functionally coupled to contraction
on day one.
Contractile Studies on Day 3
On day three, BW723C86 contracted arteries from DOCA-
high salt and Sham-high salt rats (figure 4A). There was
also a significant contraction observed to CP93129 in
arteries from DOCA-high salt rats (figure 4B). Arteries
from DOCA-low salt and Sham rats did not contract to
BW723C86 or CP93129 (figures 4A and 4B). Contraction
to 5-HT was enhanced, as defined by an increased maxi-
mal contraction, decreased threshold for contraction and/
or an increased potency, in arteries from Sham-high saltBMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/12
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Measurement of fluid consumption by day and treatment group Figure 1
Measurement of fluid consumption by day and treatment group. Vertical bars represent the mean ± sem for the number of ani-
mals indicated in parentheses. * represents statistically significant difference (p < 0.05) between the response obtained from 
day one of treatment.
Day 3
Day 5 Day 7
Sham
(N=4-6)
DOCA-
low salt
Treatment Group
300
150
0
100
50
Treatment Group Treatment Group
Sham
Sham DOCA-
low salt
DOCA-
low salt
(N=4-6) (N=4-6)
0
0
50 50
100 100
150 150
250
250 250
200
200
200
300 300
Day 1
250
Treatment Group
Sham Sham-
high salt
DOCA-
low salt
DOCA-
high salt
(N=4-7)
0
50
100
150
200
300
F
l
u
i
d
 
 
I
n
t
a
k
e
 
(
m
l
/
d
a
y
)
*
*
*
* *
Sham-
high salt
DOCA-
high salt
DOCA-
high salt
DOCA-
high salt
Sham-
high salt
Sham-
high salt
F
l
u
i
d
 
 
I
n
t
a
k
e
 
(
m
l
/
d
a
y
)
F
l
u
i
d
 
 
I
n
t
a
k
e
 
(
m
l
/
d
a
y
)
F
l
u
i
d
 
 
I
n
t
a
k
e
 
(
m
l
/
d
a
y
)BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/12
Page 4 of 15
(page number not for citation purposes)
rats (figure 4C). The arteries from the DOCA-high salt rats
showed no change in the maximal contraction to 5-HT
but demonstrated enhanced 5-HT potency (-log EC50 [M]
values 6.02 ± 0.08, 5.74 ± 0.05 DOCA-high salt day 3 and
Sham, respectively). Unexpectedly, arteries from DOCA-
low salt rats showed an increased maximal response to 5-
HT (maximal contraction 141.2 ± 11.8 % PE contraction).
Since there was no response to CP93129 and very little
response to BW723C86, this enhanced contraction to 5-
HT was surprising. However, this enhancement of 5-HT-
induced contraction in arteries from DOCA-low salt rats
only occurred on day three. These findings suggest that the
5-HT1B receptor requires the presence of elevated levels of
DOCA, salt and pressure to become functionally coupled
to contraction. 5-HT2B receptors were able to mediate con-
traction in arteries from both DOCA-high salt and Sham-
high salt rats, suggesting that the elevated levels of salt are
required to observe functional changes in the 5-HT2B
receptor.
Contractile Studies on Day 5
Experiments performed on day five of the time course
demonstrated a similar profile of results. Arteries from
DOCA-high salt and Sham-high salt rats contracted to
both BW723C86 (maximal contraction 54.3 ± 11.9 % and
46.3 ± 6.6 % of PE contraction, DOCA-high salt and
Sham-high salt, respectively) and CP93129 (maximal
contraction 35.0 ± 8.6 % and 27.8 ± 7.4 % of PE contrac-
tion, DOCA-high salt and Sham-high salt, respectively)
(figures 5A and 5B). Arteries from Sham-high salt rats also
displayed an increased maximal contraction to 5-HT
(maximal contraction 148.5 ± 11.4 % and 106.2 ± 8.7 %
of PE contraction, Sham-high salt and Sham, respec-
tively), a decrease in the threshold of activation of con-
traction and an increase in potency, and as compared to
Measurement of systolic blood pressures Figure 2
Measurement of systolic blood pressures. Data are reported in mm Hg. Points represent the mean ± sem for the number of 
experiments indicated in parentheses. * represents statistically significant difference (p < 0.05) between the response obtained 
from the Sham response on each day . + represents statistically significant difference (p < 0.05) between the response obtained 
from the day zero measurement from each respective group.
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Day 1 A: Effect of the 5-HT2B receptor agonist BW723C86 in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt and  Sham rats Figure 3
Day 1 A: Effect of the 5-HT2B receptor agonist BW723C86 in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt and 
Sham rats. B: Effect of the 5-HT1B receptor agonist CP93129 in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt 
and Sham rats. C: Effect of 5-HT in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt and Sham rats. Data are 
reported as a percentage of the initial PE 10-5 M contraction. Points represent the mean ± sem for the number of experiments 
indicated in parentheses. * represents statistically significant difference (p < 0.05) between the response obtained in the Sham 
artery.
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Day 3 A: Effect of the 5-HT2B receptor agonist BW723C86 in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt and  Sham rats Figure 4
Day 3 A: Effect of the 5-HT2B receptor agonist BW723C86 in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt and 
Sham rats. B: Effect of the 5-HT1B receptor agonist CP93129 in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt 
and Sham rats. C: Effect of 5-HT in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt and Sham rats. Data are 
reported as a percentage of the initial PE 10-5 M contraction. Points represent the mean ± sem for the number of experiments 
indicated in parentheses. * represents statistically significant difference (p < 0.05) between the response obtained in the Sham 
artery.
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Sham arteries (-log EC50 value [M] 6.06 ± 0.05 and 5.60 ±
0.07 Sham-high salt and Sham, respectively) (figure 5C).
The arteries from DOCA-high salt rats also show a
decrease in the threshold of activation of contraction (fig-
ure 5C). These results suggest that additional changes in
the contractile mechanisms utilized by 5-HT, in addition
to the 5-HT1B and 5-HT2B receptors being functionally
coupled to contraction, are required in arteries from
DOCA-high salt hypertensive rats to mediate hyperre-
sponsiveness to 5-HT.
Contractile Studies on Day 7
On day seven, arteries from DOCA-high salt rats con-
tracted to both BW723C86 (maximal contraction 57.4 ±
5.9 % of PE contraction) and CP93129 (maximal contrac-
tion 63.8 ± 7.8 % of PE contraction) (figures 6A and 6B).
Arteries from Sham-high salt rats also contracted to both
BW723C86 (maximal contraction 24.5 ± 9.4 % of PE con-
traction) and CP93129 (maximal contraction 19.6 ± 8.1
% of PE contraction) (figures 6A and 6B). Interestingly,
although the arteries from Sham-high salt rats were
exposed to both increased levels of salt and pressure, these
arteries did not contract to the same magnitude in the
presence of BW723C86 (maximal contraction 24.5 ± 9.4
% and 57.4 ± 5.9 % of PE contraction, Sham-high salt and
DOCA-high salt, respectively) and CP93129 (maximal
contraction 19.6 ± 8.1% and 63.8 ± 7.8 % of PE contrac-
tion, Sham-high salt and DOCA-high salt, respectively) as
those that are taken from DOCA-high salt rats on day
seven. Additionally, arteries from DOCA-high salt and
Sham-high salt rats both show hyperresponsiveness to 5-
HT (figure 6C). These arteries demonstrate a characteristic
increased maximal contraction (maximal contraction
130.3 ± 19.5 % and 119.5 ± 5.1 % of PE contraction,
DOCA-high salt and Sham-high salt, respectively), the
decreased threshold for contraction and the increased
potency (- log EC50 value [M] 6.41 ± 0.09, 6.13 ± 0.03 and
5.70 ± 0.07, DOCA-high salt, Sham-high salt and Sham,
respectively). These data suggest that the combined pres-
ence of elevated levels of salt, DOCA and pressure all con-
tribute to the functional changes in 5-HT1B and 5-HT2B
receptors observed in the arteries from the DOCA-high
salt hypertensive rats.
Protein Analysis Studies
To determine if upregulation of 5-HT1B and 5-HT2B recep-
tor proteins was responsible for the acquired contractility,
we performed western analysis of total aortic homoge-
nates. The authors acknowledge that the limitations of
this technique do not speak to localization of the receptor
proteins within the cell, only to the total amount of the
receptor protein present. There was no increase in 5-HT1B
receptor protein levels in any of the treatment groups at
any time point (figure 7), although there was a trend
towards increasing levels of protein in the aortic homoge-
nates from the DOCA-high salt rats. This was an unex-
pected finding as the arteries from both the DOCA-high
salt and Sham-high salt rats contract to the 5-HT1B agonist
CP93129 starting on day three of the time course. These
data suggest that although the receptor protein is upregu-
lated by 28 days of DOCA-salt treatment (13), upregula-
tion is not required to enable this receptor to participate
in contraction.
In contrast, the 5-HT2B receptor was upregulated signifi-
cantly by day 3 of DOCA-high salt treatment (figure 8).
However, 5-HT2B  receptor protein levels were not
increased in any of the other treatment groups at any time
point. Interestingly, the level of receptor protein was not
significantly increased on day 1, even though there was a
significant contraction to the 5-HT2B  receptor agonist
BW723C86 on this day. There was also no significant
increase in 5-HT2B receptor levels in the aortic homoge-
nates from the Sham-high salt rats in which contraction to
BW723C86 occurred on days 3, 5 and 7. These findings
suggest that upregulation of the 5-HT2B receptor proteins
is not absolutely required for this receptor to mediate ago-
nist-induced contraction.
Discussion
Since the isolation of 5-HT, a role for it in systemic hyper-
tension has been suggested. While the specific role which
5-HT plays in hypertension remains a controversial topic,
there is no argument that 5-HT is both a vasoconstrictor
and a mitogen. Currently, the mRNA for the 5-HT2A, 5-
HT2B, 5-HT1B. 5-HT1D, 5-HT1F and 5-HT7 receptors have
been localized to vascular smooth muscle cells. [17].
However, only the 5-HT2A receptor has been shown to
activate the mitogen-activated protein kinase (MAPK)
pathway and participate in arterial contraction under
conditions of normal blood pressure in the rat thoracic
aorta. [17]. Interestingly, the present studies suggest that
5-HT1B and 5-HT2B receptors are involved in mediating the
arterial hyperresponsiveness to 5-HT observed in hyper-
tension. This involvement appears to be due to changes
independent of the level of receptor proteins as the func-
tional response of contraction can be separated from an
increase in the level of 5-HT2B  and 5-HT1B  receptor
proteins.
Regulation of 5-HT Receptors
The studies presented here support the idea that mineralo-
corticoids combined with salt and increased blood pres-
sure, but not mineralocorticoids alone in vivo, may be
important mediators of the changes to both the level of 5-
HT2B and 5-HT1B receptor protein levels and the signaling
mechanisms utilized by these receptors. The aortic
homogenates from DOCA-salt rats showed an increase in
the level of the 5-HT2B receptor protein on days 3, 5 and 7.
Contrary to in vitro findings in which aldosterone aloneBMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/12
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Day 5 A: Effect of the 5-HT2B receptor agonist BW723C86 in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt and  Sham rats Figure 5
Day 5 A: Effect of the 5-HT2B receptor agonist BW723C86 in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt and 
Sham rats. B: Effect of the 5-HT1B receptor agonist CP93129 in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt 
and Sham rats. C: Effect of 5-HT in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt and Sham rats. Data are 
reported as a percentage of the initial PE 10-5 M contraction. Points represent the mean ± sem for the number of experiments 
indicated in parentheses. * represents statistically significant difference (p < 0.05) between the response obtained in the Sham 
artery.
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Day 7 A: Effect of the 5-HT2B receptor agonist BW723C86 in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt and  Sham rats Figure 6
Day 7 A: Effect of the 5-HT2B receptor agonist BW723C86 in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt and 
Sham rats. B: Effect of the 5-HT1B receptor agonist CP93129 in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt 
and Sham rats. C: Effect of 5-HT in aorta from Sham-high salt, DOCA-high salt, DOCA-low salt and Sham rats. Data are 
reported as a percentage of the initial phenylephrine (PE) 10-5 M contraction. Points represent the mean ± sem for the number 
of experiments indicated in parentheses. * represents statistically significant difference (p < 0.05) between the response 
obtained in the Sham artery.
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increased 5-HT2B receptor [13], the aortic homogenates
from the DOCA-low salt rats showed no increase in the
level of 5-HT2B receptor. These findings suggest that in vivo
an increase in mineralocorticoids alone is not sufficient to
upregulate the 5-HT2B receptor. Upregulation of the 5-
HT2B receptor protein in vivo may require the elevated lev-
els of salt, DOCA and pressure. On day one, arteries from
the DOCA-salt rats with normal blood pressure con-
tracted to BW723C86 but showed no increase in the level
of the 5-HT2B receptor protein.
Surprisingly, the in vivo time course experiments did not
show any increase in the level of the 5-HT1B receptor pro-
tein levels. These findings are also contrary to the in vitro
data where aldosterone incubation produced an upregula-
tion of these receptor protein levels [13]. In contrast to the
data obtained on days 1, 3, 5 and 7, after 28 days of
DOCA-high salt hypertension the 5-HT1B  and 5-HT2B
receptors are upregulated approximately 2-fold in the
aorta from DOCA-high salt hypertensive rats [13]. These
data suggest that in vivo regulation mechanisms of these
receptors and their function maybe more complicated
than the in vitro experiments suggested as elevated levels
of mineralocorticoids alone in vivo was not sufficient to
upregulate either the 5-HT1B or the 5-HT2B receptor pro-
teins. However, as our studies did not address the issue of
Top: Measurement of 5-HT1B receptor protein density in aortic homogenates from Sham, DOCA-low salt, Sham-high salt and  DOCA-high salt rats on days 1, 3, 5 and 7 Figure 7
Top: Measurement of 5-HT1B receptor protein density in aortic homogenates from Sham, DOCA-low salt, Sham-high salt and 
DOCA-high salt rats on days 1, 3, 5 and 7. Bottom: Representative western blot probed for the 5-HT1B receptor protein. Units 
are reported as arbitrary densitometry units. Vertical bars represent the mean ± sem for the number of experiments indicated 
in parentheses. * represents statistically significant difference (p < 0.05) between the response obtained in the corresponding 
Sham. Abbreviations: S = Sham; DHS = DOCA-high salt; DLS = DOCA-low salt; SHS = Sham-high salt.
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protein degradation, we can not rule out the possibility
that there is an increase in the receptor proteins that is
compensated for by an increase in protein degradation.
Additionally, it is unknown at this point if the combina-
tion of elevated salt and mineralocorticoids affects the
members of the signaling cascades used by the 5-HT1B and
5-HT2B receptors to enable enhanced contraction. This is
an intriguing possibility since the ability of the 5-HT1B and
5-HT2B receptors to mediate contraction does not appear
to be solely dependent on the level of the receptor protein.
Physiological Significance
The physiological importance of the 5-HT2B receptor is
emphasized by the finding that administration of the 5-
HT2B receptor antagonist LY272015, in vivo, decreased the
blood pressure of hypertensive DOCA-salt rats and LNNA
hypertensive rats [4,16]. Currently, studies using chronic
in vivo administration of LY272015 to determine whether
5-HT2B receptors are required for development of the
increased blood pressure have not been done. Further-
more, the chronic administration of LY272015 would
also address whether the 5-HT2B receptor was involved in
Top: Measurement of 5-HT2B receptor protein density in aortic homogenates from Sham, DOCA-low salt, Sham-high salt and  DOCA-high salt rats on days 1, 3, 5 and 7 Figure 8
Top: Measurement of 5-HT2B receptor protein density in aortic homogenates from Sham, DOCA-low salt, Sham-high salt and 
DOCA-high salt rats on days 1, 3, 5 and 7. Bottom: Representative western blot probed for the 5-HT1B receptor protein. Units 
are reported as arbitrary densitometry units. Vertical bars represent the mean ± sem for the number of experiments indicated 
in parentheses. * represents statistically significant difference (p < 0.05) between the response obtained in the corresponding 
Sham. Abbreviations: S = Sham; DHS = DOCA-high salt; DLS = DOCA-low salt; SHS = Sham-high salt.
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the smooth muscle cell hypertrophy and hyperplasia
observed in hypertension. In vivo studies with the 5-HT1B
receptor antagonists in the model of DOCA-salt hyperten-
sion have not yet been performed. However, in the model
of pulmonary hypertension, infusion of the 5-HT1B recep-
tor antagonist GR127935 (3 mg/kg/day) attenuated the
increased right ventricular pressure, right ventricular
hypertrophy and pulmonary vascular remodeling in the
hypertensive rats [12]. These findings suggest that both
the 5-HT2B and 5-HT1B receptors and their involvement in
cardiovascular diseases, such as hypertension, merit fur-
ther study.
Additional support for the importance of 5-HT2B receptors
in the cardiovascular system comes from 5-HT2B receptor
knockout mice. 5-HT2B  receptor knockout mice show
severe cardiovascular abnormalities [18–20]. Since 5-
HT2B receptors are required for morphogenesis and cell
migration, one can speculate that 5-HT2B receptors may be
important to the vascular changes observed in arteries
during the development of hypertension. No studies have
been done in the 5-HT1B receptor knockout mice examin-
ing the progression of systemic cardiovascular diseases.
Speculations on Alternative Functional Changes
These studies were the first and an important step into
understanding whether an upregulation of the 5-HT1B and
Systolic blood pressures (SBP), EC50 values and the maximal contraction to 5-HT, BW723C86 and CP93129 represented as a  percentage of phenylephrine (10 µM; PE) for Sham, Sham-high salt, DOCA-low salt and DOCA-high salt rats Figure 9
Systolic blood pressures (SBP), EC50 values and the maximal contraction to 5-HT, BW723C86 and CP93129 represented as a 
percentage of phenylephrine (10 µM; PE) for Sham, Sham-high salt, DOCA-low salt and DOCA-high salt rats. Values represent 
the means ± standard error of the mean for each group. The number of animals, data from the data set used for the 5-HT 
graphs, in each group is indicated in parentheses. * represents statistical difference from response obtained in the Sham.
Treatment Group SBP mm Hg
- log EC 50 value 
[M] for 5-HT 
Response
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124 + 7.6
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147 + 14
105 + 3.4
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0
0
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90.4 + 6.5
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5-HT2B  receptor proteins was sufficient to enable
contraction to agonists of these receptors. While the lack
of increase in the level of the 5-HT1B and 5-HT2B receptors
to correspond with the functional changes may suggest
nonspecific actions for CP93129 and BW723C86, there is
evidence to refute this idea. BW723C86 posseses pKi val-
ues of 6.2 at the 5-HT1B receptor, 6.6 at the 5-HT2A recep-
tor and 7.9 at the 5-HT2B receptor (21). There is currently
no published information about the ability of CP93129
to interact with the 5-HT2B receptor, one possible nonspe-
cificity. However, it is known that contractions mediated
by CP93129 can be inhibited with the 5-HT1B receptor
antagonist GR55562 (11). The ability of the 5-HT2B and 5-
HT1B receptors to participate in contraction without a con-
comitant upregulation of the receptor protein levels sug-
gest that changes in the signaling cascades and receptor/
effector coupling are potentially involved in this
enhanced contractility to 5-HT and agonists of the 5-HT2B
and 5-HT1B  receptors under conditions of DOCA-salt
hypertension. Currently, the ability to track changes in 5-
HT2A receptor is function is difficult due to limited tools
available which includes a lack of 5-HT2A receptor specific
agonists and antibodies.
The mechanisms by which elevated levels of salt and pres-
sure participate in the pathogenic changes in receptor
function observed in hypertension are still unclear and
were not the focus of this study. They are, however, an
area of future investigation. Future avenues of research
also include investigation of the Rho-Rho-kinase pathway
as well as the acute vs chronic effects of increased pressure
on 5-HT receptor subtypes.
Conclusion
We initially speculated that upregulation of 5-HT1B and 5-
HT2B receptor proteins were, at least partially, responsible
for the increased contractility to 5-HT seen in the arteries
from hypertensive rats. However, the results of the DOCA-
salt time course studies do not support this idea. Instead,
these data support the argument that an upregulation of
5-HT1B and 5-HT2B receptors are not necessary to observe
an increased contractile response to agonists of these
receptors. Additionally, there was an increased contractile
response to the 5-HT2B receptor agonist BW723C86 prior
to an increase in blood pressure in the DOCA-high salt
and Sham-high salt treated rats. Interestingly, the hyperre-
sponsiveness to 5-HT characteristic of hypertensive arter-
ies was observed in Sham-high salt and DOCA-high salt
arteries starting at day three. Collectively, the data pre-
sented herein suggest that 5-HT2B  receptors may be
involved in the development of DOCA-salt hypertension.
However, the precise role of these receptors in the devel-
opment of hypertension and possibly vascular remode-
ling are yet to be elucidated.
Methods
All procedures which involved animals were performed in
accordance with the institutional guidelines of Michigan
State University.
Surgical Procedures and Systolic Blood Pressure 
Measurement
All rats used were adult male Sprague-Dawley rats (0.20–
0.25 kg; Charles River Laboratories, Inc., Portage, MI). The
rats were separated into four treatment groups: DOCA-
high salt, DOCA-low salt, Sham and Sham-high salt. The
DOCA-high salt and DOCA-low salt were given a subcu-
taneous silastic implant impregnated with DOCA (200
mg/kg) and were uninephrectomized (left side, flank
incision) under isoflurane (IsoFlo, Abbott Laboratories,
N. Chicago, IL) anesthesia. Sham and Sham-high salt rats
did not receive an implant but were uninephrectomized.
Postoperatively, rats in the DOCA-high salt and Sham-
high salt groups received drinking water containing 1.0%
NaCl and 0.2% KCl. Sham and DOCA-low salt rats
received normal tap water. Animals in the DOCA-high
salt, Sham-high salt and Sham groups were fed a diet of
standard rat chow and received ad libitum access to both
food and water. Rats in the DOCA-low salt group were fed
a diet of chow containing .002 µEq NaCl/g. A baseline
blood pressure and on days 1, 3, 5 and 7 the systolic blood
pressures were measured using the standard tail cuff
method. Daily fluid intake was measured by giving a
standard amount of fluid and using a graduated cylinder
to ascertain the amount required to return to the initial
amount.
Isolated tissue bath procedure
The thoracic aorta was removed, cleaned of debris and cut
into helical strips. These strips were denuded of endothe-
lial cells and placed in isolated tissues baths containing
physiological salt solution consisting of (in mM) NaCl,
103; KCl, 4.7; KH2PO4, 1.18;MgSO4•7H2O, 1.17; CaCl2
•2H2O, 1.6; NaHCO3, 14.9; dextrose, 5.5; and
CaNa2EDTA, 0.03. Tissues were mounted on stainless
steel holders in tissue baths (50 ml) for isometric tension
recordings and placed under optimum resting tension
(1500 mg, determined previously). After a 1 hour equili-
bration, arteries were challenged with phenylephrine (10-
5 M). Tissues were then washed and the lack of an intact
endothelium was validated by observing the inability of
acetylcholine (10-6 M) to relax arteries contracted with a
half-maximal concentration of phenylephrine.
Cumulative concentration response curves to agonists
were performed. As there was no significant difference in
the contractile response to PE (10-5 M) in any group at any
day (data not shown) all the data is normalized and
reported as a percentage of the PE (10-5 M) contraction.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/12
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Western analysis
Protein isolation
The aorta was removed, cleaned, denuded of endothelial
cells and cut into helical strips. The tissue was frozen in
liquid nitrogen, pulverized in a liquid nitrogen-cooled
mortar and pestle and solubilized in a lysis buffer [0.5
mol/L Tris HCl (pH 6.8), 10% SDS, 10% glycerol] with
protease inhibitors (0.5 mM PMSF, 10 µg/ml aprotinin
and 10 µg/ml leupeptin). Homogenates were centrifuged
(11,000 g for 10 minutes, 4°C) and supernatant total pro-
tein measured (BCA, Sigma, St. Louis, MO).
Immunoblotting protocol
Supernatant (50 µg total protein per lane, 4:1 in denatur-
ing loading buffer, boiled 5 minutes) was loaded, sepa-
rated on 10% denaturing SDS-polyacrylamide gels, and
transferred to Immobilon-P membranes. Membranes
were blocked for 3–4 hours in Tris buffer saline + Tween-
20 (0.1%; TBS-T) containing 4% chick egg ovalbulmin
and 0.025% sodium azide. Mouse anti-5HT2B receptor
antibody (.5 µg/ml, Pharmingen, San Diego, CA) or
guinea pig anti-5-HT1B receptor antibody (1:1000, Chemi-
con, Temecula, CA) were incubated with blots overnight
(4°C). Following washes, secondary antibody linked to
horseradish peroxidase [anti-mouse (1:10,000, Amer-
sham Laboratories, Arlington Heights, IL) or anti-guinea
pig (1:10,000 Chemicon, Temecula, CA)] was added for
one hour and incubated with blots at 4°C. Enhanced
chemiluminescence was performed using standard rea-
gents (Amersham Laboratories, Arlington Heights, IL).
Each blot was washed and redeveloped using an α-
smooth muscle actin antibody (1:400, Oncogene
Research Products, Boston, MA; anti-mouse secondary
antibody, 1:5,000, Amersham Laboratories, Arlington
Heights, IL). Equal lane loading of protein was ensured by
comparing α-smooth muscle actin densitometry.
Data analysis and statistics
Data are presented as means ± standard error of the mean
for the number of animals in parentheses. When compar-
ing more than two groups, either a one-way ANOVA was
performed followed by a Student-Newman-Keuls post
hoc test or a two-way ANOVA was used, as was appropri-
ate. The systolic blood pressure data was analyzed with
repeated measures. In all cases, a p value less than or equal
to 0.05 was considered statistically significant.
Materials
Acetylcholine chloride, phenylephrine hydrochloride,
DOCA and 5-hydroxytryptamine hydrochloride were pur-
chased from Sigma Chemical Co. (St. Louis, MO).
BW723C86 was purchased from Tocris (Ballwin, MO).
CP93129 was a gift from Pfizer (Groton, CT, USA).
Authors' contributions
Studies were performed and analyzed primarily by AKLB.
SWW assisted with study design and analysis.
Acknowledgements
This work was supported by the NIH grant HL58489 (SWW), an Atorvas-
tatin Award (SWW) and a grant from the American Heart Association 
Award 0010194z (AKLB).
References
1. Banes A, Florian JA and Watts SW: Mechanisms of 5-
hydroxytryptamine2A receptor activation of the mitogen-
activated protein kinase pathway in vascular smooth muscle.
J Pharmacol Exp Ther 1999, 291:1179-1187.
2. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M and
Morecroft I: 5-hydroxytryptamine receptors mediating vaso-
constriction in pulmonary arteries from control and pulmo-
nary hypertensive rats. Br J Pharmacol 1996, 119:917-930.
3. Cox DA and Cohen ML: 5-hydroxytryptamine2B receptor sign-
aling in rat stomach fundus: role of voltage-dependent cal-
cium channels, intracellular calcium release and protein
kinase C. J Pharmacol Exp Ther 1995, 272:143-150.
4. Watts SW and Fink GD: 5-HT2B-receptor antagonist LY272015
is antihypertensive in DOCA-salt hypertensive rats.  Am J
Physiol 1999, 276:H944-H952.
5. Watts SW and Harris B: Is functional upregulation of the 5-
HT2B receptor in deoxycorticosterone acetate-salt treated
rats blood pressure dependent? Gen Pharm The Vasc Sys 1999,
33:439-447.
6. Craig DA and Martin GR: 5-HT1B receptors mediate potent con-
tractile responses to 5-HT in rat caudal artery. Br J Pharmacol
1993, 109:609-611.
7. Verheggen R, Hundeshagen AG, Brown AM, Schindler M and Kau-
mann AJ: 5-HT1B receptor-mediated contractions in human
temporal artery: evidence from selective antagonists and 5-
HT receptor mRNA expression.  Br J Pharmacol 1998,
124:1345-1354.
8. Lovern F, Li XF, Lytton J and Triggle C: Functional characteriza-
tion of mRNA expression of 5-HT receptors mediating con-
traction in human umbilical artery.  Br J Pharmacol 1999,
127:1247-1255.
9. Morecroft I, Heeley RP, Prentice HM, Kirk A and MacLean MR: 5-
hydroxytryptamine receptors mediating contraction in
human small muscular pulmonary arteries: importance of
the 5-HT1B receptor. Br J Pharmacol 1999, 128:730-734.
10. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T and
Edvinsson L: Characterization of 5-HT receptors in human
coronary arteries by molecular and pharmacological
techniques. Eur J Pharmacol 1999, 372:49-56.
11. Banes AK and Watts SW: Enhanced contraction to 5-HT is not
due to "unmasking" of 5-HT1B receptors in the mesenteric
artery of the DOCA-salt rat. Hypertension 2001, 38:891-895.
12. Keegan A, Morecroft I, Smillie D, Hicks MN and MacLean MR: Con-
tribution of the 5-HT1B receptor to hypoxia-induced pulmo-
nary hypertension: converging evidence using 5-HT1B
receptor knockout mice and the 5-HT1B/1D receptor antago-
nist GR127935. Circ Res 2001, 89:1231-1239.
13. Banes AK and Watts SW: Upregulation of arterial serotonin1B
and 2B receptors in deoxycorticosterone acetate-salt
hypertension. Hypertension 2002, 39:394-398.
14. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG,
Etienne N, Drouet L, Humbert M, Simonneau G and Maroteaux L:
Function of the serotonin 5-hydroxytryptamine 2B receptor
in pulmonary hypertension. Nature Medicine 2002, 8:1129-1135.
15. Sciotti V and Gallant S: Resistance to mineralocorticoid hyper-
tensive vascular disease. Hypertension 1987, 10:176-180.
1 6 . R u s s e l l  A ,  B a n e s  A K ,  B e r l i n  H ,  F i n k  G D  a n d  W a t t s  S W :  5-
hydroxytryptamine2B receptor function is enhanced in the
Nω-L-arginine hypertensive rat.  J Pharmacol Exp Ther 2002,
303:179-187.
17. Watts SW, Yang P, Banes AK and Baez M: Activation of ERK
mitogen-activated protein kinase proteins by vascular serot-
onin receptors. J Cardiovasc Pharmacol 2001, 38:539-551.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/12
Page 15 of 15
(page number not for citation purposes)
18. Choi DS, Ward SJ, Messaddeq N, Launay JM and Maroteaux L: 5-
HT2B  receptor-mediated serotonin morphogenetic func-
tions in mouse cranial neural crest cells and myocardiac
cells. Development 1997, 124:1745-1755.
19. Nebigil CG, Choi DS, Dierich A, Hickel P, Le Meur M, Messaddeq N,
Launay JM and Maroteaux L: Serotonin2B receptor is required for
heart development. Pro Natl Acad Sci USA 2000, 97:9508-9513.
20. Nebigil CG, Hickel P, Messaddeq N, Vonesch JL, Douchet MP,
Monassier L, Gyorgy K, Matz R, Andriantsitohaina R, Manivet P, Lau-
nay JM and Maroteaux L: Ablation of serotonin 5-HT2B recep-
tors in mice leads to abnormal cardiac structure and
function. Circulation 2001, 103:2973-2979.
21. Kennett GA, Bright F, Trail B, Baxter GS and Blackburn TP: Tests of
the 5-HT2B receptor agonist, BW723C86, on three rat mod-
els of anxiety. Br J Pharmacol 1996, 117:1443-1448.